Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double blind, phase 2, parallel group study - McClung, M R; Brown, J P; Diez-Perez, A (J Bone Miner Res, 2018)
et al.